:: Home   :: Contact ICare   :: Site Map          
 | Home | About ICare | Research | CTR Library | Register | Contact ICare
Breast Cancer News Pg2
Breast Cancer Breakthrough News

Previous Page

  Dec 27, 2007
Anti-PDL1 immunotherapy promising in Triple-Negative Breast Cancer 
  By , Kay Jackson, Contributing Writer, MedPage Today

INDIANAPOLIS, Dec. 27 -- A  

In patients with metastatic triple-negative breast cancer, immunotherapy with the monoclonal antibody against immune checkpoint, PD-1, appeared to be safe, tolerable, and capable of durable clinical activity according to an ongoing multicenter phase 1a study.reported Dr. Leisha Emens of Johns Hopkins University.

<READ MORE>     

SABCS: Testosterone Relieves Atrophic Vaginitis in Breast Cancer Patients
  By Charles Bankhead, Staff Writer, MedPage Today

SAN ANTONIO, Dec. 17 -- Intravaginal testosterone may offer relief from atrophic vaginitis without the risks of estrogen to breast cancer patients taking aromatase inhibitors, according to a pilot study.   <READ MORE>

SABCS: Taxane Therapy After Anthracyclines Not Demonstrably Better for Breast Cancer
  By Michael Smith, North American Correspondent, MedPage Today

SAN ANTONIO, Dec. 17 -- A course of taxanes following standard anthracycline-based chemotherapy for breast cancer had no discernible benefit, found a large British study, <READ MORE>

  Dec 17, 2007
SABCS: Earlier Diagnosis and Better Treatment Improve Male Breast Cancer Survival
  By Charles Bankhead, Staff Writer, MedPage Today

SAN ANTONIO, Dec. 17 -- Male breast cancer outcomes have improved substantially by earlier diagnoses and increased use of adjuvant therapies, two large French cohorts showed.   <READ MORE>

  Dec 13, 2007
SABCS: San Antonio Breast Cancer Symposium Meeting
  By Michael Smith, North American Correspondent, MedPage Today

SAN ANTONIO, Dec. 13 -- The anthracycline drugs -- long a mainstay of breast cancer chemotherapy -- only benefit a minority of women and should be mostly scrapped, a researcher said here.   <READ MORE>

  Dec 04, 2007
FDA Reviewers Question Safety and Efficacy of Bevacizumab (Avastin) in Breast Cancer
  By Peggy Peck, Executive Editor, MedPage Today

ROCKVILLE, Md., Dec. 4 -- Adding bevacizumab (Avastin) to paclitaxel (Taxol) for treatment of metastatic breast cancer did not extend overall survival, but did increase toxicity by more than 20% and mortality by 1.7%, FDA staffers said.   <READ MORE>

  Nov 30, 2007
Cancer Advances in Focus: Breast Cancer
  By National Cancer Institute

Thirty-Five Years Ago ... Approximately 75% of women diagnosed with breast cancer survived their disease at least 5 years.  <READ MORE>

  Nov 16, 2007
Gene Signatures Predict Breast Cancer Treatment Response in Clinical Study
  By John Gever, Contributing Writer, MedPage Today

BORDEAUX, France, Nov. 16 -- Gene-expression signatures in breast tumor samples can accurately predict which patients will not respond to two common chemotherapy regimens, researchers here found.  <READ MORE>

  Nov 13, 2007
Experimental Technique at GUMC Offers Real-Time Analysis of Breast Cancer Biopsies
  Georgetown University Medical Center

Washington, D.C. − A sophisticated microscope that offers a “real-time” 3-D analysis of tissue samples might, in the future, reduce the number of needle biopsies traditionally needed from women suspected of having breast cancer, according to recent research published at Georgetown University Medical Center’s Lombardi Comprehensive Cancer Center.  <READ MORE>

  Oct 31, 2007
ASTRO: Radiation Boost Lowers Breast Cancer Relapse Risk
  By Michael Smith, Senior Staff Writer, MedPage Today

LOS ANGELES, Oct. 31 -- Two factors increase the risk of relapse after lumpectomy for early-stage breast cancer, but a boost of radiation aimed at the tumor bed lowers that risk, researchers reported here.  <READ MORE>

  Oct 30, 2007
ASTRO: Breast Cancer Local Relapses Higher for Black Women
  By Michael Smith, Senior Staff Writer, MedPage Today

LOS ANGELES, Oct. 30 -- Black women with breast cancer are more likely to have a local relapse after a lumpectomy and radiation therapy than are white women, a researcher said here.  <READ MORE>

  Oct 29, 2007
ASTRO: Breast Cancer Severity Unaffected by Smoking
  By Michael Smith, Senior Staff Writer, MedPage Today

LOS ANGELES, Oct. 29 -- Smoking doesn't appear to affect the characteristics of breast tumors at diagnosis, a researcher said here.  <READ MORE>

  Oct 17, 2007
FDA Approves Drug for Breast Cancer Resistant to First-Line Treatments
  By Peggy Peck, Executive Writer, MedPage Today

ROCKVILLE, Md., Oct. 17 -- Bristol-Myers Squibb said its metastatic breast cancer drug ixabepilone (Ixempra) has received FDA approval for treatment of women with metastatic or locally advanced treatment-resistant breast cancer.  <READ MORE>

  Oct 12, 2007
More Prominence Urged for Heart Risks in Breast Cancer Treatment
  By Crystal Phend, Staff Writer, MedPage Today

DURHAM, N.C., Oct. 12 --Oncologists need to think heart when treating early breast cancer, according to clinicians here.  <READ MORE>

  Oct 11, 2007
  By Johns Hopkins Kimmel Cancer Center

One year after completing the first large-scale report sequencing breast and colon cancer genes, Johns Hopkins Kimmel Cancer Center scientists have studied the vast majority of protein-coding genes which now suggest a landscape dominated by genes that each are mutated in relatively few cancers.  <READ MORE>

  Sept 26, 2007
ECCO: Herceptin Pre-Surgery More Effective Than Chemo Alone in Inflammatory Breast CA
  By Ed Susman, Contributing Writer, MedPage Today

BARCELONA, Spain, Sept. 26 -- The addition of trastuzumab (Herceptin) to chemotherapy before surgery appears to allow more women with HER-2 positive inflammatory breast cancer to achieve a complete disease response than does chemotherapy alone.  <READ MORE>

  Sept 25, 2007
MR Spectroscopy After MRI Cuts Down on Benign Biopsies
  By Crystal Phend, Staff Writer, MedPage Today

NEW YORK, Sept. 25 -- Proton magnetic resonance (MR) spectroscopy may eliminate 68% of biopsies for benign nonmass breast lesions found on standard MR imaging (MRI) without missing any cancers.   <READ MORE>

  Sept 17, 2007
ASCO Breast: Circulating Tumor Cells Show Tumor Response and Relapse Risk
  By Peggy Peck, Executive Editor, MedPage Today

ROCKVILLE, Md., Sept. 17 -- The FDA has approved the osteoporosis drug raloxifene (Evista) for prevention of invasive breast cancer in high-risk or osteoporotic postmenopausal women.   <READ MORE>

  Sept 12, 2007
ASCO Breast: Circulating Tumor Cells Show Tumor Response and Relapse Risk
  By Crystal Phend, Staff Writer, MedPage Today

SAN FRANCISCO, Sept. 12 -- Circulating tumor epithelial cells may open a window on the response of breast cancer to adjuvant therapy and, possibly, the risk of relapse as well, researchers said.   <READ MORE>

  Sept 11, 2007
ASCO Breast: Circulating Tumor Cells Show Tumor Response and Relapse Risk
  By Crystal Phend, Staff Writer, MedPage Today

SAN FRANCISCO, Sept. 11 -- Neoadjuvant trastuzumab (Herceptin) may improve breast cancer response rates in combination with anthracycline-based chemotherapy, but some oncologists remain skeptical about cardiac toxicity.  <READ MORE>

  July 31, 2007
MRI Beats Mammography or Ultrasound at Detecting Breast Cancer
  By Martha Kerr, Staff Writer, MedPage Today

SEATTLE, July 31 -- Screening MRI had a higher rate of breast cancer detection than either mammography or ultrasound screening in high-risk women, but it nearly quadrupled the biopsy rate, researchers here found.   <READ MORE>

  July 25, 2007
FDA Advisers Recommend Raloxifene (Evista) for Prevention of Breast Cancer
  By Peggy Peck, Staff Writer, MedPage Today

ROCKVILLE, Md., July 25 -- An FDA advisory panel has recommended that the agency approve raloxifene (Evista) for prevention of breast cancer in high-risk postmenopausal women.   <READ MORE>

  July 24, 2007
Low Mammography Rate for Older Breast Cancer Survivors May Cost Lives
By Crystal Phend, Staff Writer, MedPage Today

BOSTON, July 24 -- Only a minority of older breast cancer survivors undergoes recommended yearly surveillance mammography, but for those who do, the risk of dying from the disease is cut by almost a third, researchers found.   <READ MORE>

  July 23, 2007
Metastatic Breast Cancer Survival Improved with Newer Therapies
  By Crystal Phend, Staff Writer, MedPage Today

VANCOUVER, British Columbia, July 23 -- Systemic therapies for metastatic breast cancer introduced over the past decade appear to have improved survival, according to the first population-based study to support this long-suspected benefit.   <READ MORE>

  July 16, 2007
FDA Okays Molecular Assay to Detect Node-Positive Breast Cancer
  By Peggy Peck, Managing Editor, MedPage Today

ROCKVILLE, Md., July 16 -- The FDA has approved a rapid molecular-based test for detecting node-positive breast cancer.   <READ MORE>

  July 11, 2007
Breast Cancer Prognosis Not Affected by BRCA Status
  By Judith Groch, Senior Writer, MedPage Today

HAIFA, Israel, July 11 -- Breast cancer survival was similar among carriers and noncarriers of BRCA1 and BRCA2 mutations in an Israeli study in which 10% of Ashkenazi women had such a susceptibility mutation, researchers reported.   <READ MORE>

  March 05, 2007
Not perfect, but progress!
  Researchers at the National Cancer Institute at Frederick have discovered a compound that could be an answer for breast cancer patients.

Originally published March 05, 2007  By Alison Walker-Baird
News-Post Staff
  FREDERICK -- Denise O'Neill, who founded a Maryland breast cancer support program, is running out of time for researchers to find a new cancer drug.  <READ MORE>

For more about Denise and her Cancer Support Groups click here.

  Herceptin treatment lowers recurrence rate in early breast cancer. Encouraging results for women with aggressive Her2-positive disease
  The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage disease when given for one year following standard chemotherapy.  <READ MORE>
  FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
  Scientists are hopeful that a new man-made antibody will be effective in significantly slowing the growth of about 25% of breast cancers. This is particularly exciting, because this 25% also happens to be the type of breast cancer that is harder to treat and which spreads more rapidly.

November 16, 2006 -Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and Drug Administration (FDA) approved Herceptin® (Trastuzumab), as part of a treatment regimen containing doxorubicin, ...  <READ MORE>

  Red Meat Consumption Associated with Increased Risk for Breast Cancer
  Boston, MA – Researchers at Brigham and Women’s Hospital (BWH) have found that eating more red meat may be associated with a higher risk for hormone receptor–positive breast cancers in premenopausal women.  This research is published in the November 13, 2006 issue of the Archives of Internal Medicine.  <READ MORE>
  Advanced Breast Cancer Patients Benefit More from Aromatase Inhibitors than Tamoxifen
  Aromatase Inhibitors (AIs) have proven superior to tamoxifen as a hormonal treatment for early-stage breast cancer in women with estrogen-sensitive tumors.  The third generation of these agents - letrozole, anastrozole, ...   <READ MORE>

Previous Page


:: 12 Element Approach ::
Explore and supplement your therapy with ICare's unique 12-Element approach to Patient Survival.

:: Breakthrough News ::
Breaking news on research for gentler, more effective therapies and information on lifesaving treatment options.

:: ICare Bulletin Board ::
View pertinent information regarding meetings and events pertaining to cancer patients. This is also a resource for contacting other patients about information and treatment options.

Breast Cancer National News
Copyright ⓒ ICare.  All rights reserved.